HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution

REFERENCES

• Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55:97–120, x.
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–2120.
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–297.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Kreissman SG, Diller L, London WB, Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study. ASCO Abstract. Vol 2007.
   Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–256.
   PubMed Web of Science ®Google Scholar
• Park JR, Slattery J, Gooley T, Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol. 2000;35:719–723.
   Google Scholar
• Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg. 2004;39:931–936.
   Google Scholar
• Browne M, Kletzel M, Cohn SL, Seshadri R, Reynolds M. Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma. J Pediatr Surg. 2006;41:271–276.
   Google Scholar
• Castleberry RP, Kun LE, Shuster JJ, Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991;9:789–795.
   PubMedGoogle Scholar
• Kushner BH, Wolden S, LaQuaglia MP, Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001;19:2821–2828.
   PubMed Web of Science ®Google Scholar
• Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer. 2004;100:1268–1275.
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Swift PS, Selch M, Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28–39.
   PubMedGoogle Scholar
• Simon T, Hero B, Bongartz R, Schmidt M, Muller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol. 2006;182:389–394.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007–1013.
   PubMed Web of Science ®Google Scholar
• Dominici C, Deb G, Angioni A, Peripheral blood stem cells in children with solid tumors, II: immunocytologic detection of tumor cells in bone marrow and peripheral blood stem cell harvests. Anticancer Res. 1993;13:2573–2575.
   Google Scholar
• Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood. 1990;76:1879–1883.
   PubMed Web of Science ®Google Scholar
• Kreissman SG, Seeger RV, Grupp SA, A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. ASCO Abstract. Vol 2008.
   Google Scholar
• Flandin I, Hartmann O, Michon J, Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma: a study of the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys. 2006;64:1424–1431.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Potschger U, Hartman O, 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 2008;41(Suppl 2):S118–S127.
   PubMed Web of Science ®Google Scholar
• George RE, Li S, Medeiros-Nancarrow C, High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896.
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Kane DJ, Einhorn PA, Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res. 1991;366:203–211.
   PubMedGoogle Scholar
• Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003;197:185–192.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Tucker C, The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–940.
   PubMed Web of Science ®Google Scholar
• Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914–5920.
   PubMed Web of Science ®Google Scholar
• Hank JA, Surfus J, Gan J, Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol. 1994;15:29–37.
   PubMed Web of Science ®Google Scholar
• Gilman AL, Ozkaynak MF, Matthay KK, Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009;27:85–91.
   PubMed Web of Science ®Google Scholar
• Osenga KL, Hank JA, Albertini MR, A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006;12:1750–1759.
   PubMed Web of Science ®Google Scholar
• Shusterman S, Gillies SD, Hank JA, Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. ASCO Abstract. Vol 2008.
   Google Scholar
• Park JR, Digiusto DL, Slovak M, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825–833.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270.
   PubMed Web of Science ®Google Scholar
• Matthay KK, DeSantes K, Hasegawa B, Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229–236.
   Google Scholar
• Matthay KK, Quach A, Huberty J, Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approach to neuroblastoma therapy phase I study. J Clin Oncol. 2009;27:1020–1025.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Tan JC, Villablanca JG, Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24:500–506.
   PubMed Web of Science ®Google Scholar
• Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci. 2007;8:755–765.
   PubMed Web of Science ®Google Scholar
• Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol. 2006;24:3423–3430.
   PubMed Web of Science ®Google Scholar
• Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138–1146.
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–193.
   PubMed Web of Science ®Google Scholar
• M. Fouladi M, Sun J, Ingle AM, A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. ASCO Abstract. Vol 2008.
   Google Scholar
• Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169:107–114.
   PubMed Web of Science ®Google Scholar
• Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847–854.
   PubMed Web of Science ®Google Scholar
• Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992;52:1364–1368.
   PubMed Web of Science ®Google Scholar
• Ho R, Eggert A, Hishiki T, Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002;62:6462–6466.
   PubMed Web of Science ®Google Scholar
• Evans AE, Kisselbach KD, Liu X, Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol. 2001;36:181–184.
   PubMedGoogle Scholar
• Evans AE, Kisselbach KD, Yamashiro DJ, Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res. 1999;5:3594–3602.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–935.
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–978.
   PubMed Web of Science ®Google Scholar